Genexine, Inc. (KOSDAQ: 095700)

Market Cap	257.40B
Revenue (ttm)	5.81B
Net Income (ttm)	-54.53B
Shares Out	41.45M
EPS (ttm)	-1,320.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	80,360
Open	6,210.00
Previous Close	6,200.00
Day's Range	6,210.00 - 6,400.00
52-Week Range	5,840.00 - 11,870.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Genexine

Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 86
• Stock Exchange: KOSDAQ
• Ticker Symbol: 095700

Financial Performance

In 2023, Genexine's revenue was 4.43 billion, a decrease of -72.57% compared to the previous year's 16.14 billion. Losses were -66.87 billion, 19.5% more than in 2022.